New hope for kids with brittle bones: experimental drug enters final testing
NCT ID NCT06079359
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 28 times
Summary
This study tests a new medicine called ALXN1850 in 30 children aged 2 to 12 who have hypophosphatasia, a rare genetic condition that weakens bones. The drug is given as a shot under the skin and compared to a placebo (fake treatment) to see if it helps heal bone problems. All children in the study have not received the standard treatment before.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Kansas City, Missouri, 64108, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Nedlands, 6009, Australia
-
Research Site
Parkville, 3052, Australia
-
Research Site
Brussels, 1020, Belgium
-
Research Site
Brasília, 71625-009, Brazil
-
Research Site
Porto Alegre, 90610-261, Brazil
-
Research Site
Recife, 50740-465, Brazil
-
Research Site
Salvador, 40050-410, Brazil
-
Research Site
São Paulo, 01409-902, Brazil
-
Research Site
São Paulo, 05403-900, Brazil
-
Research Site
Calgary, Alberta, T2E 7Z4, Canada
-
Research Site
Winnepeg, Manitoba, R3E 3P4, Canada
-
Research Site
Beijing, 100045, China
-
Research Site
Guangzhou, 510623, China
-
Research Site
Shanghai, 2000127, China
-
Research Site
Shenzhen, 518053, China
-
Research Site
Helsinki, 00290, Finland
-
Research Site
Ashkelon, 7830604, Israel
-
Research Site
Chihuahua City, 31238, Mexico
-
Research Site
Lodz, 93-338, Poland
-
Research Site
Bucharest, 011863, Romania
-
Research Site
Madrid, 28046, Spain
-
Research Site
Vitoria-Gasteiz, 01009, Spain
-
Research Site
Stockholm, 17176, Sweden
-
Research Site
Taipei, 100, Taiwan
-
Research Site
Ankara, 06560, Turkey (Türkiye)
-
Research Site
Bursa, 16059, Turkey (Türkiye)
-
Research Site
Erzurum, 25240, Turkey (Türkiye)
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Birmingham, B4 6NH, United Kingdom
Conditions
Explore the condition pages connected to this study.